Anbio Biotechnology (NNNN) fundamentals score
In Vitro & In Vivo Diagnostic Substances · Healthcare · Listed on NASDAQ
Overall: 5.3 out of 10, Mixed fundamentals
- Growth: 3.2/10
- Profitability: 7.4/10
- Financial health: 7.5/10
- Earnings quality: 2.1/10
- Valuation: not scored
Scores are calculated from Anbio Biotechnology’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom Inc. (DXCM): 8.8/10
- Compugen Ltd. (CGEN): 8.7/10
- Exelixis, Inc. (EXEL): 8.7/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group Inc. (HCSG): 8.5/10